| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $149.5M | -0.3% |
| Cost of Revenue | $0 | -100.0% |
| R&D Expense | $147.2M | -16.9% |
| SG&A Expense | $39.2M | -44.9% |
| Operating Income | -$72.8M | +34.1% |
| Pre-tax Income | -$75.3M | -14.0% |
| Income Tax | -$672K | -171.2% |
| Net Income | -$74.6M | -11.4% |
| EPS (Basic) | -$1.18 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $57.2M | -68.7% |
| Accounts Receivable | $13.4M | +210.4% |
| Inventory | $7.9M | — |
| Current Assets | $219.9M | +1.1% |
| Total Assets | $256.8M | -1.8% |
| Current Liabilities | $43.1M | -22.4% |
| Total Liabilities | $201.3M | +38.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$81.0M | -18.5% |
| Capital Expenditures | $1.9M | -48.4% |
| Investing Cash Flow | -$114.1M | -176.4% |
| Financing Cash Flow | $69.5M | +7141.0% |
| Free Cash Flow | -$83.0M | -15.1% |
| -10.3% |
| EPS (Diluted) | -$1.18 | -10.3% |
| Stockholders' Equity |
| $55.6M |
| -52.1% |